Sernova (TSXV:SVA; OTC:SEOVF; FSE/XETRA:PSH) appointed 25-year pharmaceutical industry executive, Frank Shannon, as VP of clinical development and regulatory Affairs.
Mr. Shannon most recently served as VP clinical development, regulatory affairs and quality at Ripple Therapeutics, a spin-out of Interface Biologics, where he served in the same capacity since 2006. He also has held senior clinical/regulatory positions at Baxter International, St. Jude Medical, Boehringer-Ingelheim, Hoffmann-La Roche/Roche Laboratories, Genentech Canada and Ciba-Geigy Canada.
“With Sernova’s clinical success to date in Type 1 diabetes, we look forward to leveraging Mr. Shannon’s strategic expertise to further progress our ongoing Type 1 diabetes program, including our current U.S. Phase 1/2 Cell Pouch clinical trial, and our local immune protection and stem cell technology initiatives, as well as driving clinical development of our other therapeutic programs in thyroid disease and hemophilia A,” Dr. Philip Toleikis, president and CEO of Sernova, said in a statement.
Mr. Shannon said he is looking forward to positively impact Sernova’s expanding clinical programs as the company advances its novel leading regenerative medicine therapeutic programs.
